Literature DB >> 19880282

Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length.

Helga Gardarsdottir1, Patrick C Souverein, Toine C G Egberts, Eibert R Heerdink.   

Abstract

OBJECTIVES: When constructing drug treatment episodes using drug-dispensing databases, duration and the number of prescriptions belonging to a single treatment episode need to be defined. We investigated how different methods used to construct antidepressant treatment episodes influence their median estimated length. STUDY DESIGN AND
SETTING: A follow-up study among adult antidepressant drug users, identified from the Dutch PHARMO RLS, starting selective serotonin reuptake inhibitor (SSRI) use in 2001 was conducted. The influence of varying lengths of the prescription overlap and the gap between prescriptions (number of days or percentage of prescription duration) on the median antidepressant treatment episode length were investigated.
RESULTS: Of the 16,053 SSRI starters, 65.1% were female and mean age was 45.7 (SD: 17.2) years. Median antidepressant treatment episode length doubled when the gap length was expanded from 0 to 10 days. For short gap lengths the episode interquartile range was 40% to 200% larger when overlap was accounted for and when percentage of prescription duration gap length was used.
CONCLUSION: Differences in median episode length exist between methods that account for or disregard prescription overlap. These differences are of importance for studies that focus on drug exposure-outcome relationships and could have consequences for epidemiological analysis. Copyright 2010. Published by Elsevier Inc.

Mesh:

Substances:

Year:  2009        PMID: 19880282     DOI: 10.1016/j.jclinepi.2009.07.001

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  33 in total

1.  Characteristics and drug use patterns of older antidepressant initiators in Germany.

Authors:  Kathrin Jobski; Niklas Schmedt; Bianca Kollhorst; Jutta Krappweis; Tania Schink; Edeltraut Garbe
Journal:  Eur J Clin Pharmacol       Date:  2016-10-18       Impact factor: 2.953

2.  Measuring psychotropic drug exposures in register-based studies--validity of a dosage assumption of one unit per day in older Finns.

Authors:  Maria Rikala; Sirpa Hartikainen; Leena K Saastamoinen; Maarit Jaana Korhonen
Journal:  Int J Methods Psychiatr Res       Date:  2013-05-16       Impact factor: 4.035

3.  Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance.

Authors:  K Berencsi; A Sami; M S Ali; K Marinier; N Deltour; S Perez-Gutthann; L Pedersen; P Rijnbeek; J Van der Lei; F Lapi; M Simonetti; C Reyes; M C J M Sturkenboom; D Prieto-Alhambra
Journal:  Osteoporos Int       Date:  2019-11-06       Impact factor: 4.507

4.  Methods for constructing treatment episodes and impact on exposure-outcome associations.

Authors:  Laura Pazzagli; Lena Brandt; Marie Linder; David Myers; Panagiotis Mavros; Morten Andersen; Shahram Bahmanyar
Journal:  Eur J Clin Pharmacol       Date:  2019-11-22       Impact factor: 2.953

5.  Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study.

Authors:  F F Alharbi; P C Souverein; M C de Groot; A H Maitland-van der Zee; A de Boer; O H Klungel
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

6.  Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case-Control Study.

Authors:  Wiebke Schäfer; Christina Princk; Bianca Kollhorst; Tania Schink
Journal:  Drug Saf       Date:  2019-09       Impact factor: 5.606

Review 7.  Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.

Authors:  Anton Pottegård; Søren Friis; Til Stürmer; Jesper Hallas; Shahram Bahmanyar
Journal:  Basic Clin Pharmacol Toxicol       Date:  2018-01-15       Impact factor: 4.080

8.  Adherence to preventive statin therapy according to socioeconomic position.

Authors:  Helle Wallach-Kildemoes; Morten Andersen; Finn Diderichsen; Theis Lange
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

9.  Fracture risk in nursing home residents initiating antipsychotic medications.

Authors:  Sally K Rigler; Theresa I Shireman; Galen J Cook-Wiens; Edward F Ellerbeck; Jeffrey C Whittle; David R Mehr; Jonathan D Mahnken
Journal:  J Am Geriatr Soc       Date:  2013-04-16       Impact factor: 5.562

10.  Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.

Authors:  E Martín-Merino; I Petersen; S Hawley; A Álvarez-Gutierrez; S Khalid; A Llorente-Garcia; A Delmestri; M K Javaid; T P Van Staa; A Judge; C Cooper; D Prieto-Alhambra
Journal:  Osteoporos Int       Date:  2017-12-03       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.